Uses of Rizax

Rizax belongs to the class of psychotropic drugs, used to treat memory impairments. Let's learn about the uses and doses of Rizax through the article below.

Rizax is made in the form of tablets, with the main ingredient being Donepezil HCl 5mg. Donepezil is a specific and reversible inhibitor of acetylcholinesterase, a major cholinesterase in the brain. Donepezil inhibits the enzyme Cholinesterase, which increases the concentration of Acetylcholine in the brain, while Acetylcholine is a neurotransmitter involved in memory and learning. In vitro, donepezil is 1000 times more potent at inhibiting acetylcholinesterase than butyrylcholinesterase, an enzyme that exists mainly outside the central nervous system. The drug is well absorbed from the gastrointestinal tract, peak plasma concentrations are reached within 3-4 hours after oral administration. Steady state drug concentrations are reached 3 weeks after initiation of treatment.

Rizax is used to treat mild to moderate dementia in Alzheimer's disease. Do not use Rizax in case of hypersensitivity to donepezil, piperidin derivatives or any of the ingredients in the drug.

Adults and the elderly: Starting dose of 5mg / time / day, should be maintained for at least 1 month to be able to evaluate the effectiveness of treatment as well as achieve steady state drug concentrations. After 1 month of evaluating the effectiveness of treatment at the dose of 5mg/day, it can be increased to 10mg/time/day. Doses above 10 mg/day have not been studied in clinical trials. Discontinue use if no effect is seen. No dose adjustment is required in patients with renal impairment as it does not affect the clearance of the drug. For patients with mild and moderate hepatic impairment, the dose should be adjusted according to the tolerance level of each patient. There are no study data for severe hepatic impairment. Do not give this medicine to children. How to take the drug: Take the medicine in the evening before going to bed.

When using Rizax, you may experience some of the following undesirable effects:
Abdominal pain, nausea, vomiting, loss of appetite, indigestion, diarrhea. Itching, rash on the skin. Fatigue, headache, dizziness, somnolence, insomnia, muscle cramps, sweating, tremors, fainting. Rarely, angina, atrioventricular block, sinoatrial block, bradycardia, peptic ulcer, gastrointestinal bleeding, seizures, and extrapyramidal symptoms have been reported. Psychiatric disorders: hallucinations, depression, agitation, aggressive behavior have also been reported. Secret urine. Slight increase in serum creatine kinase. Increase liver enzymes. The use of acetylcholinesterase inhibitors can cause weight loss, so weight should be monitored during treatment. Nervous system effects such as leg pain when immobilized (restless legs), mumbling, and slurred speech may be seen in the elderly when the dose is increased to 10 mg/day. This condition is reversible upon discontinuation of the drug and reappears upon resumption of the drug. Urinary incontinence may occur with the use of donepezil. When using Rizax, if the patient experiences any serious side effects, stop taking the drug and contact the treating doctor or immediately go to a medical facility for timely treatment.

When using Rizax simultaneously may interact with some of the following drugs:
Donepezil has the potential to affect drugs with anticholinergic effects. When concomitant treatment with the following drugs is likely to cause synergistic effects: Succinylcholine, cholinergic agonists, beta-blockers acting on cardiac conduction or other neuromuscular blocking agents. The plasma concentration of donepezil may be increased when co-administered with CYP3A4 inhibitors (itraconazole, ketoconazole, erythromycin) and CYP2D6 inhibitors (fluoxetin, quinidine). Plasma concentrations of donepezil may be reduced when co-administered with enzyme inducers such as carbamazepine, rifampicin, phenytoin and alcohol. Antimuscarinic agents are antagonistic to anticholinesterase agents, however the combination of the two is sometimes used to treat dementia in patients with acute urinary incontinence.

When using Rizax, it should be noted in the following cases:
Caution in people with gastrointestinal obstruction, urinary tract, after gastrointestinal or bladder surgery, parkinsonism, convulsions. Donepezil is considered a cholinesterase inhibitor, capable of enhancing the succinylcholine-type muscle relaxant effect during anesthesia. Due to the pharmacological action of the drug, cholinesterase inhibitors can stimulate the parasympathetic system (slow the heart rate). Therefore, it should be used with caution in patients with “sinus node failure syndrome” or other cardiac conduction conditions. Persons at high risk for peptic ulcers, such as those with a history of ulcers or those taking concomitant non-steroidal anti-inflammatory drugs (NSAIDs), should be carefully monitored for gastrointestinal symptoms. However, clinical studies showed that donepezil did not increase the incidence of gastrointestinal ulceration or gastrointestinal bleeding compared with placebo. Drugs with choline-like effects may cause urinary retention, but this has not been observed in donepezil clinical trials. Drugs with choline-like effects are thought to cause generalized convulsions. However, seizures can also be a manifestation of Alzheimer's disease. Because of their choline-like effects, cholinesterase inhibitors should be used with caution in patients with a history of asthma or chronic obstructive pulmonary disease. The drug should be used with caution in pregnant or lactating women, only when absolutely necessary and after carefully weighing the benefits of treatment and the possible risks to the fetus or young child. The drug can cause fatigue, dizziness, drowsiness, so caution should be taken when requiring high concentration such as driving or operating machinery. In addition to the above information, if you have any questions about Rizax, you can contact your doctor for advice and answers.